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Abstract 
We report a 53-year-old male patient who underwent paravertebral mass excision at the 
D10–11–12 vertebral levels in 2007. The histopathological evaluation of the mass 
showed the presence of neuroblastoma. The patient was diagnosed with stage IV 
neuroblastoma. He received 6 courses of chemotherapy and exhibited a stable course 
until March 2010. When he was reevaluated in March 2010, progression in the metastatic 
lesion as well as local recurrence was detected. The patient, who was restarted on 
chemotherapy, developed progressive weakness and loss of sensation of the lower 
extremity. The neurosurgical investigation revealed an irreversible loss in motor 
functions. The patient is currently on symptomatic treatment. 
 
Introduction 
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood that 
originates from the neural crest. The mean age of diagnosis is 2 years, with 35% of the 
cases occurring before the age of 1 year and the remaining occurring before 10 years of 
age. NB affects children in the first year of life and is very rare among adolescents and 
young adults. The most common site of involvement for NB is the abdomen (60%), 
followed by the thorax (15%), pelvis (5%) and the cervical sympathetic chain (5%). 
Approximately 20% of all NBs originate from the posterior mediastinum. The treatment 
of NB is surgical chemotherapy or radiotherapy. Currently, there is no standard treatment 
protocol for the adult NB. The treatment protocol established for children remains 
inappropriate for adults and particularly, localized disease involves a more aggressive 
course in adults compared to children. In NB, the treatment should be performed 
according to the pediatric guidelines because no treatment recommendations exist for the 
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A 53-year-old male patient underwent paravertebral mass excision at the D10–11–12 vertebral levels 
in 2007 (fig. 1a, b). The histopathological evaluation of the mass showed the presence of NB (fig. 2a, b). 
Neuron-specific enolase was >370 ng/ml. Upon presentation with the complaints of pain in the right hip 
and claudication after 1 year, a mass lesion with indefinite edges that surrounded the right iliac bone 
and led to the destruction of cortex was detected. Tru-cut biopsy obtained from the mass was consistent 
with metastatic NB. 
The patient was diagnosed with stage IV NB. Combination chemotherapy with a CADO/CDDP-
VP16 regimen according to the pediatric protocol was started with cyclophosphamide (CPM 1,500 
mg/m
2 per cycle), doxorubicin (AD 60 mg/m
2 per cycle), vincristine (2 mg per cycle), cisplatin (CDDP 
100 mg/m
2 per cycle), and etoposide (VP16 500 mg/m
2 per cycle) with G-CSF. Treatment consisting of 
D1 adriamycin 75 mg/m
2, D2 cyclophosphamide 1,800 mg/m
2, D1 vincristine 2 mg and D1–5 
ifosfamide 1,800 mg/m
2, D1–5 etoposide 100 mg/m
2, D1–5 Mesna 1,800 mg/m
2 was planned for the 
patient. Upon detection of progression in the size of the mass detected in the pelvis in the patient, who 
received this therapy for 4 courses, D1 cisplatin 80 mg/m
2, D1–3 etoposide 100 mg/m
2 were started 
concomitantly with radiotherapy. The patient, who received 6 courses of chemotherapy, exhibited a 
stable course until March 2010. When he was reevaluated in March 2010, progression in the metastatic 
lesion as well as local recurrence was detected. The patient, who was restarted on chemotherapy, 
developed progressive weakness and loss of sensation of the lower extremity. The neurosurgical 
investigation revealed an irreversible loss in motor functions. The patient is currently on symptomatic 
treatment. 
Discussion 
NB is the most common extracranial solid tumor in childhood that originates from the 
neural crest. The mean age of diagnosis is 2 years with 35% of the cases occurring before 
the age of 1 year and the remaining occurring before 10 years of age [1]. They represent 
8–10% of all childhood cancers. NB affects children in the first year of life and is very rare 
among adolescents and young adults. NB, ganglioneuroblastoma and ganglioneuroma are 
the tumors that originate from the primordial neural crest cells. NB involves 3 classical 
histopathological types by differentiation and maturation. These include the NB, 
ganglioneuroblastoma and ganglioneuroma. While most cases have a nonestablished 
etiology of NB, environmental factors appear to be involved. The most common site of 
involvement for NB is the abdomen (60%), followed by the thorax (15%), pelvis (5%) and 
the cervical sympathetic chain (5%) [2]. Approximately 20% of all NBs originate from the 
posterior mediastinum [3, 4]. The symptoms of the disease show variability based on the 
site of involvement; however, they most commonly include the manifestations of 
compression due to the mass and bone pain due to metastasis. 
NB may originate from any site in the sympathetic nervous system. The site of the 
primary tumor shows variability based on the age of the patients at the time of diagnosis. 
While a majority of the primary tumors are of intra-abdominal localization (65%), in 
children below 1 year of age, the tumors involve the intra-thoracic region and the neck. 
There is no specific localization observed in adults. Primary tumor may not be detected in 
approximately 1% of the cases. NBs can metastasize widely through both lymphatic and 
vascular routes. The most common sites of metastasis are bone marrow, bones, lymph 
nodes, liver, skin, and testes. There is a greater frequency of metastases among adolescents 
in unusual parenchyma of the lung or brain, which are affected more frequently in other 
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In contrast to the malignant forms, ganglioneuroma is more common among adults. 
Ganglioneuroma is a benign tumor and is usually asymptomatic. The symptoms usually 
occur due to the compression created by the tumor. Due to the vasoactive intestinal 
polypeptides it secretes, diarrhea, hypertension, hypokalemia or masculinization may be 
observed rarely [5, 6]. Adolescents more frequently have an advanced stage of the disease, 
a low excretion of urinary catecholamines, absence of biological abnormalities and 
chronic but fatal disease [7]. 
Ganglioneuroma may rarely include the components of ganglioneuroblastoma, NB 
and feochromocytoma and be transformed to the malignant peripheral nerve sheath 
tumor [8]. Since it may be radiologically mixed with many tumors, it is quite difficult to 
establish the diagnosis postoperatively. Therefore, these masses can mostly be diagnosed 
postoperatively by histopathological investigation. 
Compared to NBs occurring in children, NBs observed in adults occur more frequently 
as an advanced-stage and metastatic disease [9]. 
The prognosis of the patients with NB depends on numerous variables; the most 
important of them are age of the patient at diagnosis and the stage of the tumor, DNA 
pyloidi, molecular signer, histology, and chromosome 1p, 11q, 17g aberration. The low 
age at diagnosis and the low stage are 2 important favorable prognostic features. 
The treatment of NB is surgical chemotherapy or radiotherapy. Currently, there is no 
standard treatment protocol for adult NB. The treatment protocol established for children 
remains inappropriate for adults and particularly, localized disease involves a more 
aggressive course in adults compared to children. In NB, the treatment should be 
performed according to the pediatric guidelines because no treatment recommendations 
exist for the treatment of NB in adults [10, 11]. 
Although currently there are no standard treatment guidelines for patients with NB in 
adulthood, complete surgical resection is sufficient for low risk and nonmetastatic 
tumors, but combination therapy with chemotherapy and radiotherapy is necessary for 
disseminated and recurrent diseases. The treatment includes vincristine 1.5 
mg/m
2/dose/day, etoposide 150 mg/m
2/dose/day, carboplatin 170 mg/m
2/dose/day or 
cyclophosphamide 200 mg/m
2/dose/day, Mesna 3 × 40 mg/m
2/dose, etoposide 60 
mg/m
2/dose/day, cisplatin 20 mg/m
2/dose/day or vincristine 0.05 mg/kg /dose/day, DTIC 
(Dacarbazine) 7 mg/kg/dose/day, ifosfamide 50 mg/kg/dose/day, %100 Mesna 50 
mg/kg/dose/day, adriamycin 1 mg/kg/dose/day. 
Treatment was comprised of high-dose cyclophosphamide (at a dose of 140 mg/kg), 
topotecan (at a dose of 8 mg/m
2), and vincristine (at a dose of 0.067 mg/kg or 2 mg/m
2, 
whichever was lower; maximum dose, 2 mg) (HD-CTV) at refractory or recurrent NB. 
Response to HD-CTV as salvage therapy is significantly less likely in adolescents/adults 
and in children with NB that is persistent or progressing on treatment rather than newly 
recurrent off treatment. These findings are broadly applicable and should be considered 
when designing, and interpreting the results of, phase 2 studies [12]. 
Stage III and IV tumors are often initially treated with chemotherapy followed by 
tumor resection. Because of a lack of experience in adults, the treatment followed 
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combination, include alkylating agents (cyclophosphamide/ifosfamide), platinum-based 
agents (cisplatin/carboplatin), etoposide, adriamycin and vinca-alkaloids. 
Clinical data on the survival outcomes of adult patients (defined as 20 years of age and 
older) with NB are scarce due to the rarity of the disease. Small, single institution reports 
have described worse outcomes for adults than pediatric patients. 
Currently, there are no standard treatment guidelines for patients with adult NB. In 
patients with metastatic disease and at late stages of disease, multimodal therapy should 
include surgical resection, radiotherapy, and outpatient chemotherapy. Follow-up of 
patients with NB should include metabolic imaging studies and tumor marker 
determination. The collection and evaluation of data on adult patients with this rare 
tumor are warranted in order to optimize treatment strategies. Whether more intensive 
treatment or myeloablative therapy with stem cell support will improve the outcome of 
NB in adults is unclear. 
Radiotherapy 
Radiotherapy has no role in low-risk NB. Stage IV NB is not a localized disease and 
systemic treatment is required. The efficacy of radiotherapy in the high-dose 
chemotherapeutical protocols has not been established yet. The efficacy of RT should be 
weighted against the potential late effects (growth retardation, scoliosis, secondary 
malignancy) and the benefit-hazard ratio should be considered. The role of radiotherapy 
in high risk is more marked compared to the moderate risk group. 
Surgery 
Surgical intervention is significantly involved in the treatment of NB, and complete 
excision of the tumor or minimization of the tumor to the highest extent possible has a 
favorable effect on the prognosis [13]. 
Immunology and Neuroblastoma 
Based on the fact that the human immune system may be deficient in recognizing and 
destroying the NB cells, active and passive immunotherapies are being developed. For 
passive immunotherapy, anti-GD2 monoclonal antibodies and genetically modified T 
cells are used. For active immunotherapy, IL-2, modified tumor cell vaccines, dendritic 
cell vaccines, DNA vaccines and monoclonal antibodies with non-specific signaling (anti-
CTLA-4, anti-CD40) are used. Treatment protocols based on immunotherapy may also 
be used [14, 15]. 
The other novel therapeutical approaches in the treatment of NB include the use of 
retinoic acid, anti-N-myc therapies and angiogenesis-regulating therapies and the use of 
histone deacetylase inhibitors. Retinoic acid derivatives stimulate the differentiation of 
neuroblasts, thereby contributing to the treatment. N-myc is an intracellular component. 
When silencing RNA (siRNA) is placed in the structure of the N-myc, the cell 
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presence of the N-myc recipients on the cell surface has been demonstrated and an 
increase in their number achieved by stimulation has been observed to lead to an 
increased programmed cell death and an increased responsiveness in these cells against 
hydroxyurea. Anti-VEGF antibodies may provide a narrowing in the tumor by decreasing 
vascularization. In malignancies, DNA methylation and histone acetylation is increased. 
Histone deacetylase inhibitors (HDAC1) interfere with the development of the tumor by 
preventing the occurrence of this effect. 
Patient-specific therapeutical strategies are being developed to increase the survival 
rates, reduce the late effects and increase the quality of life in NB [16, 17]. 
Disclosure Statement 







Fig. 1. a, b Nuclear vesiculation, nucleolar prominence, extension and eosinophilic amphophilic 
features observed in the cytoplasm. 
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Fig. 2. a, b On the T1- and T2-weighted axial cross-sections, at the T4, T5 and T6 levels, the tumor 
extends from the right neural foramina to the spinal duct and creates a marked compression on the 
spinal cord from the right posterolateral section with a 5.5-cm long component. In addition, there are 
diffuse lymphadenomegalies in the paravertebral region. 
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